Clinical Trials Directory

Trials / Unknown

UnknownNCT03244930

Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation

Low Dose Plerixafor Plus G-CSF Efficiency in Mobilizing Stem Cells From Lymphoma and Myeloma Patients for Autologous Peripheral Blood Transplantation

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
20 (estimated)
Sponsor
Hospital Universitario Dr. Jose E. Gonzalez · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Plerixafor, is added to mobilizing chemotherapy and G-CSF to overcome poor stem cell mobilization. We want to demonstrate that half of the commonly prescribed dose can be safely administered once as a single dose in first attempt leading to apheresis yields of \>2 x 106 CD34+ cells/kg body weight.

Detailed description

Plerixafor, is added to mobilizing chemotherapy and G-CSF to overcome poor stem cell mobilization. Consecutive patients in autologous transplant protocol will receive mobilization consisted of daily subcutaneously G-CSF 10 mg/kg for 4 days and plerixafor 0.12 mg/kg as a single dose 11 hours prior to initiation of apheresis. HSC collection was performed with a Cobe Spectra® or Spectra Optia® apheresis system. The planned target blood volume to be processed will be 4-fold total blood volume calculated according to patients' weight and size. Peripheral blood CD34+ counts will be analyzed using flow cytometry. For each ASCT, we aimed for target yields of at least 2 x 106 CD34+cells/kg. Toxicities and engraftment will be documented.

Conditions

Interventions

TypeNameDescription
DRUGPlerixafor 0.12 mg/kgSubcutaneously G-CSF 10 mg/kg for 4 days. At day four SC plerixafor 0.12 mg/kg as a single dose 11 hours prior to initiation of aphaeresis.

Timeline

Start date
2017-05-10
Primary completion
2018-05-10
Completion
2018-06-10
First posted
2017-08-10
Last updated
2017-08-10

Locations

1 site across 1 country: Mexico

Source: ClinicalTrials.gov record NCT03244930. Inclusion in this directory is not an endorsement.